|Publisher DOI:||10.1042/BCJ20160916||Title:||Reengineering of the human pyruvate dehydrogenase complex: from disintegration to highly active agglomerates||Language:||English||Authors:||Guo, Jin
|Issue Date:||16-Dec-2016||Publisher:||Portland Press||Source:||Biochemical Journal 5 (474): 865-875 (2017-03-01)||Journal or Series Name:||Biochemical journal||Abstract (english):||The pyruvate dehydrogenase complex (PDC) plays a central role in cellular metabolism and regulation. As a metabolite-channeling multi-enzyme complex it acts as a complete nanomachine due to its unique geometry and by coupling a cascade of catalytic reactions using 'swinging arms'. Mammalian and specifically human PDC (hPDC) is assembled from multiple copies of E1 and E3 bound to a large E2/E3BP 60-meric core. A less restrictive and smaller catalytic core, which is still active, is highly desired for both fundamental research on channeling mechanisms and also to create a basis for further modification and engineering of new enzyme cascades. Here, we present the first experimental results of the successful disintegration of the E2/E3BP core while retaining its activity. This was achieved by C-terminal α-helixes double truncations (eight residues from E2 and seven residues from E3BP). Disintegration of the hPDC core via double truncations led to the formation of highly active (approximately 70% of wildtype) apparently unordered clusters or agglomerates and inactive non-agglomerated species (hexamer/ trimer). After additional deletion of N-terminal 'swinging arms', the aforementioned C-terminal truncations also caused the formation of agglomerates of minimized E2/E3BP complexes. It is likely that these 'swinging arm' regions are not solely responsible for the formation of the large agglomerates.||URI:||http://hdl.handle.net/11420/3241||ISSN:||1470-8728||Institute:||Bioprozess- und Biosystemtechnik V-1||Type:||(wissenschaftlicher) Artikel||Funded by:||Funded by the German Federal Ministry of Education and Research (BMBF, grant [031A128]). The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under BioStruct-X (grant agreement No 283570).|
|Appears in Collections:||Publications without fulltext|
Show full item record
checked on Sep 20, 2020
Add Files to Item
Note about this record
Items in TORE are protected by copyright, with all rights reserved, unless otherwise indicated.